- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04756297
Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia
Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Prospective Diagnostic Cohort Study
Extreme preterm infants (GA ≤ 28+6 weeks) are at high risk for bronchopulmonary dysplasia (BPD) that has been associated with significant long-term impairment. Lung ultrasound score (LUSs) has the potential to early identify infants at high risk of developing BPD who may benefit from early intervention.
Aim: To assess if LUS score can be utilized to predict the development of BPD in infants born at ≤ 28+6 weeks, early in their postnatal course, when the disease is likely to be most amenable to therapeutic intervention.
Study Overview
Status
Conditions
Detailed Description
Background and Importance: Despite advances in neonatal care and improved survival among immature infants, bronchopulmonary dysplasia (BPD) remained a serious complication among preterm neonates born at <29 weeks' gestational age. A variety of therapies including antenatal steroid, surfactant administration, high-frequency ventilation, postnatal steroid (systemic and inhaled), and vitamin A supplementation have been studied as means to prevent BPD. Ideally, interventional studies aim to prevent or reduce BPD should include criteria for selecting infants at highest risk for BPD while excluding infants at low risk. Recently, Lung ultrasound severity score (LUSs) has shown in few studies to be a promising tool for assessing lung aeration and for early prediction of preterm infants with evolving BPD. These studies have a major limitation as it includes infants at low risk for BPD (> 28 weeks gestational age). In this study, we will assess the accuracy of LUSs for early identification BPD among extreme preterm infants born at <29 weeks' GA.
Study procedure In this prospective observational study, our aim is to recruit a large cohort of extreme premature neonates (born at ≤ 28+6 weeks gestational age), and sequentially perform an "early-diagnostic assessments "on day 3 of age. Subsequent LUS assessment will be performed at 7 days (+/- 1 day) of age and the third LUS assessment will be at 14 (+/-2 days of age). Assessment will be done in the same manner as described by Cattarossi et.al. Basically, each lung will be divided into 3 zones (upper anterior, lower anterior, and lateral) and will be examined using a L20 linear probe to perform a longitudinal lung scan (Fig 1). Additionally, we will score each zone (score 0-to 3 points) according to the modified LUS score by Brat et.al [20]. Based on the LUS pattern in each lung zone the total score can range from 0 to 18 for the 6 zones of both lungs. As summarized in figure 2 the LUS score will include signs that can be used to diagnose TTN, RDS or identify early changes of BPD.
We will record this data for babies enrolled in the study, along with their relevant medical data. At the end of this study, we will divide the cohort into those who developed BPD and those who did not as per currently used standard criteria and will compare the results of new LUS severity score obtained at earlier time points. Prediction models will be created including variables associated with BPD development at each time point with and without inclusion of lung US severity score.
Regarding LUS assessment a Zonare Ultrasound machine (Z.One PRO ultrasound) with a high-frequency (L20-5) linear probe will be used. This high-frequency probe gives excellent resolution and adequate penetration in these small infants. We decided to start LUS scanning at day 3 of age as most of these babies are at risk for intraventricular hemorrhage and minimal handling especially during the first 3 days is highly recommended.
All LUS assessments will be undertaken at the same time using a standard aseptic technique and without too much handling of the infants. Approval will be obtained from the Research Ethics Board (REB) at Sinai Health System and Health sciences Centre-Winnipeg. Parents will be approached for consent before enrollment.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3C3H8
- Health Sciences Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X5
- Mount Sinai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
GA ≤ 28+6 weeks Admitted to the NICU at Mount Sinai Hospital or Health sciences Centre-Winnipeg consent obtained.
Exclusion Criteria:
Infants who are born at > 28 weeks GA, or have congenital or chromosomal abnormalities, or parents declined consent will be excluded.
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess accuracy of LUSs for early identification of BPD in extreme preterm infants
Time Frame: 2 weeks after birth
|
The primary outcome of this study is to assess predictive characteristics of LUS score: Sensitivity, specificity, positive and negative predictive value, likelihood ratio and c-statistics of LUS score. Assessment of BPD at 36 weeks will be done as per currently used standard criteria for BPD. The primary outcome of this study is to assess predictive characteristics of LUS score: Sensitivity, specificity, positive and negative predictive value, likelihood ratio and c-statistics of LUS score. Assessment of BPD at 36 weeks will be done as per currently used standard criteria for BPD. LUS will be conducted at D3, 7 and 14 of life |
2 weeks after birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess predictive characteristics of LUS score integration in clinical variables derived model to see which model has higher predictive characteristics
Time Frame: 2 WEEKS
|
Different predictive models will be constructed to identify which model best predict BPD
|
2 WEEKS
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Prakesh Shah, MD, Mount Sinai Hospital- Toronto, ON, Canada
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-0072-E
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchopulmonary Dysplasia (BPD)
-
Cynthia McEvoyUniversity of Florida; University of California, San Francisco; Thrasher Research... and other collaboratorsCompletedBronchopulmonary Dysplasia (BPD)United States
-
Children's Hospital of Eastern OntarioThe Hospital for Sick Children; Hannover Medical School; MOUNT SINAI HOSPITAL; St... and other collaboratorsRecruitingLung Function | BPD - Bronchopulmonary DysplasiaCanada
-
PediatrixPhoenix Children's Hospital; Banner HealthActive, not recruitingBPD - Bronchopulmonary DysplasiaUnited States
-
University of FloridaCompletedPreterm Infant | Barotrauma | BPD - Bronchopulmonary DysplasiaUnited States
-
Jennifer ShepherdThe Gerber FoundationActive, not recruitingIntubation | Apnea of Prematurity | Hemodynamic Instability | BPD - Bronchopulmonary DysplasiaUnited States
-
New York Medical CollegeCompletedBPD - Bronchopulmonary DysplasiaUnited States
-
Baystate Medical CenterRecruitingRespiratory Distress Syndrome, Newborn | Prematurity | BPD - Bronchopulmonary DysplasiaUnited States
-
Stanford UniversityCompletedHypertension, Pulmonary | Bronchopulmonary Dysplasia (BPD)United States
-
The Hospital for Sick ChildrenRecruitingPulmonary Hypertension | NEC | BPD - Bronchopulmonary DysplasiaCanada
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingRespiratory Distress Syndrome | Bronchopulmonary Dysplasia (BPD) | Prematurity; Extreme | NeonatalUnited States